Get notified when PASG files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Collaboration Termination After Less Than One Year (new) — The Gemma agreement launched in July 2024 and was terminated by May 2026, suggesting the partnership failed to meet expectations or the company is pivoting strategy.
- Office Exit With Termination Fee (new) — Paying $2.3M to exit a lease early, combined with prior subleasing, signals significant operational contraction and potential cash preservation efforts.
Passage Bio terminates Gemma collaboration, exits Philadelphia office for $2.3M fee
Filed May 27, 2026 · Period ending May 21, 2026 · ~1 min read
Key Changes
-
high
Company ended its research collaboration with Gemma Biotherapeutics, terminating work on Huntington's disease and Temporal Lobe Epilepsy programs plus options for four additional CNS indications. The agreement had been active since July 2024.
Item 1.02 verify on EDGAR → -
medium
Passage Bio paid $2.3 million to exit its 37,000 square foot Philadelphia office lease early, which was set to run until December 2031. The space had been largely subleased since late 2023, indicating prior downsizing.
Item 1.02 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Partner
Trade PASG commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · May 27, 2026 · How we verify